-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

160 Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort StudyClinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Bispecific Monoclonal Antibodies in Myeloma
Hematology Disease Topics & Pathways:
Biological therapies, Research, Translational Research, Plasma Cell Disorders, Diseases, Therapies, Lymphoid Malignancies
Saturday, December 10, 2022: 12:45 PM

Emma Searle1*, Hang Quach2, Sandy W. Wong, MD3, Luciano J. Megala Costa, MD, PhD4, Cyrille Hulin5*, Wojciech Janowski6*, Jesus Berdeja, MD7, Sébastien Anguille8*, Jeffrey V. Matous, MD9, Cyrille Touzeau10*, Anne-Sophie Michallet, MD, PhD11*, Marla Husnik12*, Deeksha Vishwamitra13*, Zhuolu Niu14*, Julie Larsen15*, Lingling Chen13*, Jenna D. Goldberg16*, Rakesh Popat17* and Andrew Spencer18

1The University of Manchester, Manchester, United Kingdom
2University of Melbourne, St. Vincent’s Hospital Melbourne, Melbourne, VIC, Australia
3UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
4University of Alabama at Birmingham Hospital, Vestavia, AL
5Hôpital Haut Leveque, University Hospital, Pessac, France
6Calvary Mater Newcastle, Waratah, NSW, Australia
7Sarah Cannon Research Institute, Nashville, TN
8Vaccine and Infectious Disease Institute, University of Antwerp, Edegem, Belgium, Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium
9Colorado Blood Cancer Institute, Denver, CO
10Centre Hospitalier Universitaire de Nantes, Nantes, France
11Centre Hospitalier Lyon Sud, Hospices Civils, LYON, France
12Janssen Research & Development, San Diego, CA
13Janssen Research & Development, Spring House, PA
14Janssen Research & Development, Shanghai, China
15Janssen Research & Development, Los Angeles, CA
16Janssen Research & Development, Raritan, NJ
17University College London Hospitals NHS Foundation Trust, London, United Kingdom
18Monash University, Melbourne, Australia

Introduction: Teclistamab (tec) is an off-the-shelf, B-cell maturation antigen (BCMA) × CD3 bispecific antibody that redirects CD3+ T cells to mediate T-cell activation and subsequent lysis of BCMA-expressing multiple myeloma (MM) cells. The combination of daratumumab (dara) and lenalidomide (len) plus dexamethasone is approved for the treatment of MM. Both dara and len have immunomodulatory effects that may enhance the function of tec, potentially resulting in enhanced antimyeloma activity in a broader population of patients. We present initial safety and efficacy data for patients with MM who received tec in combination with dara and len (tec-dara-len) in a phase 1b multicohort study (MajesTEC-2; NCT04722146).

Methods. Patients were eligible for tec-dara-len if they had received 1–3 prior lines of therapy (LOT), including a proteasome inhibitor and immunomodulatory drug. In this cohort, patients received weekly doses of tec (0.72 or 1.5 mg/kg with step-up dosing) plus the approved schedules of dara 1800 mg + len 25 mg. Responses were investigator assessed per International Myeloma Working Group criteria and adverse events (AEs) by CTCAE v5.0, except for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which were graded per ASTCT guidelines.

Results: 32 patients received tec-dara-len (0.72 mg/kg, n=13; 1.5 mg/kg, n=19). At the data cutoff (July 11, 2022), median follow-up was 5.78 months (mo; range, 1.0–10.4) and median treatment duration was 4.98 mo (range, 0.10–10.35). Median age was 62 years (range, 38–75); 87.5% were male. All patients had received prior MM treatment; median prior LOT was 2 (range, 1–3), and 31.3% were anti-CD38 exposed. The most frequent AE was CRS (81.3% [n=26]). All CRS events were grade 1/2, and 95% of the events occurred during cycle 1 treatment doses. Median time to onset was 2 days (range, 1–8) and median duration was 2 days (range, 1–22). No ICANS events were reported. Other frequent AEs (≥25.0% across both dose levels) were neutropenia (75.0% [n=24]; grade 3/4: 68.8% [n=22]), fatigue (43.8% [n=14]; grade 3/4: 6.3% [n=2]), diarrhea (37.5% [n=12]; all grade 1/2), insomnia (31.3% [n=10]; grade 3/4: 3.1% [n=1]), cough (28.1% [n=9]; all grade 1/2), hypophosphatemia (25.0% [n=8]; all grade 1/2), and pyrexia (25% [n=8]; grade 3/4: 6.3% [n=2]). The frequency of febrile neutropenia was 12.5% (n=4). Infections occurred in 24 patients (75.0%; grade 3/4: 28.1% [n=9]). The most common infections were upper respiratory infection (21.9% [n=7]), COVID-19 (21.9% [n=7]), and pneumonia (21.9% [n=7]). Three patients (9.4%) had COVID-19 pneumonia. One patient (3.1%) discontinued due to an AE (COVID-19) considered unrelated to study drugs; this patient died due to COVID-19. The overall response rate (ORR) was 13/13 evaluable patients (median follow-up, 8.61 mo) at 0.72 mg/kg and 13/16 evaluable patients (median follow-up was less mature at 4.17 mo) at 1.5 mg/kg. Very good partial response or better was achieved in 12 patients at the 0.72 mg/kg dose and was not mature for the 1.5 mg/kg group. Median time to first response was 1.0 mo (range, 0.7–2.0). Preliminary pharmacokinetic concentrations of tec in combination with dara-len were similar to those seen with tec monotherapy. Tec-dara-len treatment led to proinflammatory cytokine production (induction of interleukin-6, soluble interleukin-2Rα, interferon-γ, and tumor necrosis factor-α) and T-cell activation (upregulation of programmed cell death protein-1 and CD38 on peripheral T cells).

Conclusions: Tec-dara-len was well tolerated, with a safety profile consistent with tec or dara-len individually. Promising ORR supports the potential for this combination to have enhanced early disease control through the addition of tec. These data warrant further investigation. The randomized phase 3 MajesTEC-7 study will compare tec-dara-len vs the combination of dara, len, and dexamethasone in patients with NDMM ineligible or not intended for autologous stem cell transplant as initial treatment.

Disclosures: Searle: Abbvie: Honoraria; Janssen: Honoraria; Shattuck Labs: Membership on an entity's Board of Directors or advisory committees. Quach: Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees, Other: receipt of free drug for investigator-initiated study, Research Funding; Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: receipt of free drug for investigator-initiated study, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; CSL: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Research Funding; Antengene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: leadership or fiduciary role, receipt of free drug for investigator-initiated study , Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: leadership or fiduciary role , Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: leadership or fiduciary role, receipt of free drug for investigator-initiated study , Research Funding. Wong: Catalent Biologics: Consultancy; Genentech: Research Funding; Caelum: Research Funding; Bristol Myers Squibb: Research Funding; Janssen: Research Funding; GSK: Research Funding; Fortis: Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees; Dren Bioscience: Consultancy; Patient Discovery: Research Funding. Megala Costa: Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Adaptive Biotechnologies: Consultancy, Honoraria; AbbVie: Research Funding; Sanofi: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Genentech: Research Funding. Hulin: Amgen: Honoraria; BMS: Honoraria; Sanofi: Honoraria; Janssen: Honoraria; Takeda: Honoraria; GSK: Honoraria. Janowski: Janssen-Cilag Amgen Astra-Zeneca: Consultancy, Honoraria. Berdeja: Novartis: Research Funding; Incyte: Research Funding; GlaxoSmithKline: Research Funding; Lilly: Research Funding; Genentech: Research Funding; Celgene: Consultancy, Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; Legend Biotech: Consultancy; Fate Therapeutics: Research Funding; EMD Sorono: Research Funding; Ichnos Sciences: Research Funding; CARsgen: Research Funding; Kite Pharma: Consultancy; SecuraBio: Consultancy; Takeda: Consultancy, Research Funding; Acetylon: Research Funding; Amgen: Research Funding; Poseida: Research Funding; C4 Therapeutics: Research Funding; Karyopharm: Research Funding; Janssen: Consultancy, Research Funding; AbbVie: Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Cartesian Therapeutics: Research Funding; Celularity: Research Funding; 2Seventy bio: Research Funding; Zentalis: Research Funding; Teva: Research Funding; Bluebird bio: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding. Matous: BeiGene: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees. Husnik: Johnson & Johnson/ Janssen Pharmaceutical: Current Employment. Niu: Janssen: Current Employment. Larsen: Employee of Janssen Pharmaceuticals.: Current Employment. Chen: Janssen: Current Employment. Goldberg: Janssen: Current Employment, Current equity holder in private company. Popat: Takeda: Research Funding; Janssen, Takeda, Celgene, and GSK: Honoraria; Janssen, Takeda, GSK: Other: Travel expenses from Janssen, Takeda, GSK; Janssen: Honoraria; GSK: Honoraria, Research Funding; Roche: Honoraria; BMS: Honoraria; Takeda, AbbVie, GlaxoSmithKline, and Celgene: Consultancy. Spencer: Amgen: Consultancy, Honoraria; Haemalogix: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Honoraria.

OffLabel Disclosure: at the time of abstract submission, teclistamab is being investigated for the treatment of multiple myeloma but is not yet not approved

*signifies non-member of ASH